Medical network, June 9, on June 6, fosun medicine and fosun international issued a joint, fosun medicine and its controlling shareholders fosun has according to the listing rules to hkex joint application, splitting the fosun medicine to seek some Suggestions of the wholly-owned subsidiary Sisram, and gained independence in the stock exchange main board listing approval, while the Hong Kong stock exchange has confirmed fosun medicine and fosun international advice can be split and listed. 

 

Sisram was a subsidiary of fosun pharmaceuticals in Israel in 2013, and on May 27, it acquired Alma, an Israeli medical-beauty equipment company, through Sisram. When it bought Alma, fosun pharmaceuticals said it would be on its own for 54 months, at the end of 2017. 

 

The pharmaceutical industry is divided into four sectors: pharmaceutical industry, pharmaceutical business, medical service, medical device and medical diagnosis. Which platform is the pharmaceutical industry, fosun pharma subject and pharmaceutical business is mainly sinopharm draw, will be listed separately Sisram split out now, will become galaxies medical instrument platform. 

 

Start the m&a model 

 

When Sisram is completed, it will further increase its acquisition of medical devices in accordance with the practices of the complex galaxy and its plans for the platform. Over the past years, fosun has completed the development, production, sales platform and medical instrument platform for medical devices. 

 

Fosun medicine in its 2016 earnings in the description of the medical equipment business, mainly including dental products (their own products and agent), blood transfusion and surgical supplies, medical hairdressing apparatus and instruments, surgical products. 

 

Dental is fosun medicine earlier into the field of instrument, its was established in 2002, fosun dental division is a subsidiary of fosun medicine oral professional enterprises, the main agent Germany BEGO VERTX, Netherlands and Denmark 3 shape scan (mouths series), such as the United States Stratsys brand, it relies on the perfect business network and clinical technical resources, fosun dental division in the front rank in the domestic market. At the same time, fosun pharmaceutical also actively promotes the dental business from the import products agency to the dental material, the equipment development and manufacturing. 

 

In addition to the agent in the field of dentistry, fosun medicine also has a medical equipment agent platform, the mutually beneficial health care, is mainly engaged in high-end imported medical equipment supplies sales agents, blood transfusion equipments and operation research and development, manufacturing, sales and marketing. In addition, on the basis of agent, fosun medicine for the mutual benefit platform integrates production and sales of medical equipment supplies and China business and high-end medical equipment agent for the sale of the business. 

 

It is worth mentioning that in May this year, fosun medicine medical service platform united family, announced that its parent, the sino-american mutual benefit has reached an agreement with fosun medicine, to fosun pharma wholly-owned holding can accept co., LTD. Transfer medical 30% stake held by us mutual benefit. The adjustment was done for the Sisram listing. 

 

Opposite in medical equipment beauty is relying on its $221 million takeover of the world's largest medical beauty laser equipment company Alma, and it is worth noting that the acquisition is fosun medicine to medical equipment manufacturing, research and development is an important step in the development. Alma, which has a mature market system and market leader, operates in 60 countries and regions, including the us and Germany, with a revenue of 780 million yuan in 2016. 

 

In addition to the above has been carried out of business, after galaxy also earlier this year to $90 million (RMB 619 million) bought Goldcup80 % equity, as a result, fosun medicine for European respiratory equipment brand Breas, enter respiratory markets. In June 2016, fosun also completed a c-round investment in Spirosure, a silicon valley respiratory disease testing company. 

 

For the development of the medical equipment platform, fosun medicine in its 2016 annual report, says 2017 will be the increasing investment, continue to strengthen medical equipment research and development, manufacture and sales, Sisram group, Alma Lasers will further speed up the development of medical treatment instrument and the sale, to explore together with other business sectors and business model innovation, in order to realize the extension of equipment supply to the service. At the same time, the group will continue to play the advantages of international aspect, in the existing enterprises abroad as a platform, on the basis of actively integrating business and expanding cooperation with foreign enterprises to seek domestic and foreign outstanding equipment enterprise investment opportunities and the introduction of high-end medical apparatus and instruments, with accurate health as the goal, so as to realize the scale of the medical equipment business growth. 

 

Will the medical diagnosis be broken up? 

 

Fosun medicine in for their own business description, often put together medical equipment and medical diagnosis, but Sisram will include the business? Fosun medicine said in a statement, Sisram prospectus by editing the application version is expected to be since June 6, 2017 in the Hong Kong stock exchange website browse and download, but is not on the stock exchange website facebook king to see the file. 

 

As early as 2015 by the end of the board of directors meeting, the proposal can refer them to the general meeting of shareholders holding subsidiaries and biotech initial public offerings and H shares listed on the Hong Kong stock exchange to host, but there has been no substantive progress after the message to appear. As a result, the judgment on fosun's medicine is likely to split the medical diagnosis business. Fosun medicine is the domestic earlier start for in vitro diagnostic business enterprise, its biochemical diagnosis, immune diagnosis, molecular diagnosis, and other fields have a comprehensive layout, its related companies including fosun long, the creatures, Shanghai star yao and Shanghai star, etc. 

 

Fosun's long march is the investment management platform of the company's medical diagnostics division. Shanghai fosun long medical science co., LTD., founded in 1989, is a collection of product research and development, production and sales of in vitro diagnostic reagents and laboratory and diagnostic instruments and equipment in the integration of municipal high-tech enterprises, is currently the fosun pharma wholly-owned holding enterprises. The long march has formed analysis of clinical chemistry reagents, enzyme-linked immunoassay reagent, immune transmission turbidimetric analysis reagent, flesh and supporting electrolyte analyzer reagents and other products series, become the domestic one of the most influential brand in vitro diagnostic reagent, sales and after-sales network all over the country. 

 

Founded in 2001, it became the holding subsidiary of fosun's 50.1 per cent stake in 2010. The sub-energy organism relies on its own innovation, successfully developed the diagnostic technology platform of the practical gene-chip, and has pioneered the industrialization of gene chip technology in China. In the influence of the Mediterranean anemia detection series, the creatures become more relevant national standards drafting unit, and established the first domestic genetic disease national reference plate. 

 

In addition to the already developed medical diagnostics business, fosun is also seeking out quality targets in the field of external diagnostics in international markets. In 2012, the listed south Korean listed company SD Biosensor (currently held 18.77%), and became an agent for SD Biosensor in China, increasing the technology platform for rapid diagnosis. Companies to invest in the United States in 2013 Saladax Biomedical nearly $22.5 million and become the single largest shareholder (currently 24.74%), with the company's China distribution rights and rights of product manufacturing and perfect the company in the layout of the tumor chemotherapy drug testing products. In addition, the company also invested in the infectious diseases and cancer etc Genefirst, Germany multiple bacteria identification in the field of molecular Diagnostics in the field of Miacom Diagnostics and TB vendor OXFD for in vitro diagnostic products and services. 

 

There is no clear message of the current medical diagnosis of the sub-biological platform. But in the case of Sisram, which is now split, it may be a slow start. But it is not hard to see, fosun medicine in various fields is not the layout of the "point", but as system construction, from this perspective, as long as there is a suitable opportunity, fosun pharma will choose to break up the listed. In the case of fosun's long-sleeved capital operations, these platforms are bound to spark a wave of mergers and acquisitions if they are pushed to market.